A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1. In phase Ib study, the safety and tolerability of BL-B01D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be evaluated.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat (faza Ia) lub od 18 lat (faza Ib)
- •Przewidywany czas przeżycia co najmniej 3 miesiące
- •Nowotwór zaawansowany lub z przerzutami, który nie odpowiada na standardowe leczenie lub pacjent do niego nie kwalifikuje się
- •Co najmniej jeden zmierzalny guz
- •Dobra ogólna kondycja zdrowotna (ECOG 0-1)
- •Poprzednie leczenie przeciwnowotworowe zakończyło się, a efekty uboczne wróciły do minimum
- •Prawidłowe wyniki badań krwi i funkcji nerek, wątroby i szpiku kostnego
- •Chęć uczestnictwa i podpisanie zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- August 27, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (6)
Beijing Cancer Hospital
Beijing, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Jinan Central Hospital
Jinan, China
West China Hospital, Sichuan University
Chengdu, China
Tianjin Medical University General Hospital
Tianjin, China
Zhejiang Cancer Hospital
Hangzhou, China
Trial contact
Sa Xiao, PHD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.